Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup
Provided by
Dow Jones
Health-care companies rose as optimism about a boom in obesity drugs regained momentum.
Novo Nordisk shares ticked up after the maker of obesity injection Wegovy unveiled a research project aimed at adding up to two more obesity treatments to its large pipeline, which already includes a long list of experimental obesity drugs being tested in clinical trials.
Takeda Pharmaceutical reported a fourth-quarter loss and forecast a drop in annual net profit due partly to restructuring expenses.
Embecta shares were rose after the drugmaker boosted its projection for growth in fiscal year 2024.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
May 09, 2024 17:26 ET (21:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis